Course: An Evolving Landscape for Newly Diagnosed CLL: Individualizing Treatment Strategies in the Community
CME Credits: 1.00
Released: 2026-07-31
Chronic lymphocytic leukemia (CLL) is a myeloproliferative disease characterized by the progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Incidence varies by geographic location and race/ethnicity, with higher rates reported among White Americans and in several rural states. Fortunately, advances in our understanding of CLL have led to the identification of prognostic and predictive biomarkers that can aid treatment decisions, and the availability of novel targeted agents has significantly reshaped guideline recommendations. However, gaps in care remain in community oncology settings. This on-demand CME/CE activity highlights best practices for management of newly diagnosed CLL, including biomarker-driven treatment selection in the first-line setting and optimal use of novel agents. Strategies to address barriers in community-based settings and improve patient-centered, shared decision-making will also be discussed. This enduring activity is a recorded session from Oncology Congress that took place on June 13, 2026.
Upon completion of this activity, participants should be better able to:
View Full Course